New Microbiol. 2011;34(2):109–46.PubMed 5. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15):1951–60.PubMedCentralPubMedCrossRef 6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, December 1, 2009. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0. Accessed Dec 2013.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef see more 8. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral
therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral P005091 molecular weight therapy (HAART) regimens in predicting adherence. JAIDS. 2004;36(3):808–16.PubMed 9. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169–77.PubMedCrossRef 10. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. PI3K inhibitor JAIDS. 2002;31(Suppl 3):S98–102.PubMed 11. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naïve individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3):266–71. 12. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with
higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–40.PubMedCentralPubMedCrossRef 13. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5):282–92.PubMedCrossRef 14. Aragão F, Vera J, Vaz Pinto I. Cost effectiveness of third agent class in treatment-naïve human immunodeficiency virus-infected L-NAME HCl patients in Portugal. PLOS one. 2012;7(9):e44774. 15. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371–8.PubMedCrossRef 16. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixeddose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9(2):103–14.PubMedCrossRef 17. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158–63.PubMedCrossRef 18.